The Serbian Institute of Virology Torlak, Russian Direct Investment Fund and the Generium company signed an agreement of technologies transfer for the production of the Russian Sputnik V vaccine, TASS reports citing the minister responsible for innovation and technology in the Serbian government, the head of the intergovernmental committee for cooperation with Russia Nenad Popovich.
The Torlak Institute today signed an agreement of technology transfer with the Russian Direct Investment Fund (RDIF) and the Russian pharmaceutical company Generium, due to which the Russian side transmits to the Serbian side data on the procedures and technologies necessary for the production of the Sputnik V vaccine in the Republic of Serbia. From that moment, data related to the production of the Sputnik V vaccine, which was developed by the Russian Gamalei Center, were discovered for the Torlak Institute. We are talking about sensitive and secret data that only partners with great mutual trust can exchange, “the minister said.
He also said that in April, the Torlak Institute of Virology will produce three trial series of the Sputnik V vaccine. Samples will be sent to Russia for verification. Upon confirmation of the quality of the products, the Serbian Institute will start vaccine production.
“We expect this to happen before May 20 this year,” the minister added and noted that Serbia will become the first country in Europe to start Russian vaccine production.
“This is a historic moment for our country. Due to our Russian friends, Serbia can save the health and lives of its citizens. And, very importantly, this is the beginning of the renewal of our country’s sovereignty in the production of vaccines, which will be an important resource for any state in the future, “Popovich concluded.